Ascendis Pharma (ASND) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon technology, aiming to develop treatments for metabolic and cardiovascular diseases, including a monthly TransCon Semaglutide product for obesity and type 2 diabetes. The agreement could bring Ascendis up to $285 million in milestone payments, along with sales-based royalties. Novo Nordisk will handle the clinical development and commercialization, with Ascendis focusing on early-stage research.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.
